EFFECT OF ACUTE ADMINISTRATION OF INSULIN-LIKE GROWTH FACTOR I IN PATIENTS WITH LARON-TYPE DWARFISM

EFFECT OF ACUTE ADMINISTRATION OF INSULIN-LIKE GROWTH FACTOR I IN PATIENTS WITH LARON-TYPE DWARFISM

Biosynthetic insulin-type growth factor I (IGF-I) was given as an intravenous bolus of 75 μg/kg to 9 patients with Laron-type dwarfism. Rapid onset of hypoglycaemia (-45% of basal level) was associated with a reduction in plasma insulin (-55% of basal level); thus, the lack of growth hormone recepto...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 1988-11, Vol.332 (8621), p.1170-1172
Hauptverfasser: Laron, Z., Erster, B., Klinger, B., Anin, S.
Format: Artikel
Sprache:eng
Schlagworte:
Dwarfism
Medical research
Pharmaceuticals industry
Physical growth
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Biosynthetic insulin-type growth factor I (IGF-I) was given as an intravenous bolus of 75 μg/kg to 9 patients with Laron-type dwarfism. Rapid onset of hypoglycaemia (-45% of basal level) was associated with a reduction in plasma insulin (-55% of basal level); thus, the lack of growth hormone receptors in this condition does not apply to IGF-I receptors and post-receptor pathways. Long-term treatment may therefore be beneficial in Laron-type dwarfism.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(88)90236-X